Melvin Sharoky, a director and managing member of Padonia LLC, sold 5,000 shares of Insmed Inc. (NASDAQ: INSM) on August 17, 2026, generating proceeds of $637,650 at prices ranging from $127.51 to $127.61 per share.
The disposal occurred amid a broader pullback in Insmed’s stock, which fell to $123.86 following the transaction. Sharoky retains direct ownership of 246,081 shares, with additional indirect holdings through family custodial accounts totaling 21,820 shares.
Insmed’s financial performance remains robust, with revenue surging 186% year-over-year to $1.14 billion in the last twelve months. Gross profit margin stands at 83%, supported by strong contributions from its lead drugs. BRINSUPRI generated $309.2 million in the second quarter, while ARIKAYCE reported $116.3 million, an 8% increase from the prior year.
The company raised its full-year 2026 revenue guidance for BRINSUPRI to between $1.25 billion and $1.4 billion, with combined peak sales for its three lead assets now estimated to exceed $14 billion. Analysts have responded positively to these developments. Mizuho raised its price target to $195 while maintaining an Outperform rating, and H.C. Wainwright reiterated a Buy rating with a $220 target.
Regulatory progress has also bolstered Insmed’s outlook. Japan recently approved BRINSUPRI for non-cystic fibrosis bronchiectasis in patients aged 12 and older, expanding its commercial footprint in a key market.
